Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hs 578T | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0011 | uM | 7864.042 | 0.9840 | 0.9784 | 1.4812 | |
| Hs 578T | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00548 | uM | 7864.042 | 0.9949 | 0.9931 | 1.4812 | |
| Hs 578T | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0274 | uM | 7864.042 | 1.0413 | 1.0554 | 1.4812 | |
| Hs 578T | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.137 | uM | 7864.042 | 0.9593 | 0.9446 | 1.4812 | |
| Hs 578T | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.685 | uM | 7864.042 | 1.0935 | 1.1244 | 1.4812 | |
| LY2 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 7865.018 | 0.8093 | 0.6748 | 1.1920 | |
| LY2 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 7865.018 | 0.3172 | -0.2368 | 1.1920 | |
| LY2 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 7865.018 | 0.9062 | 0.8414 | 1.1920 | |
| LY2 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.000219 | uM | 7865.018 | 1.0213 | 1.0357 | 1.1920 | |
| LY2 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.0011 | uM | 7865.018 | 0.4148 | -0.0440 | 1.1920 | |
| LY2 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.00548 | uM | 7865.018 | 0.9415 | 0.9013 | 1.1920 | |
| LY2 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.0274 | uM | 7865.018 | 0.9806 | 0.9674 | 1.1920 | |
| LY2 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.137 | uM | 7865.018 | 0.3420 | -0.1870 | 1.1920 | |
| LY2 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.685 | uM | 7865.018 | 0.6454 | 0.3852 | 1.1920 | |
| LY2 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 9536.006 | 1.0109 | 1.0174 | 1.2564 | |
| LY2 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 9536.006 | 1.0970 | 1.1530 | 1.2564 | |
| LY2 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 9536.006 | 1.0535 | 1.0846 | 1.2564 | |
| LY2 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.000219 | uM | 9536.006 | 1.0277 | 1.0440 | 1.2564 | |
| LY2 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.0011 | uM | 9536.006 | 0.5578 | 0.2568 | 1.2564 | |
| LY2 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.00548 | uM | 9536.006 | 1.0119 | 1.0188 | 1.2564 | |
| LY2 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.0274 | uM | 9536.006 | 0.9993 | 0.9988 | 1.2564 | |
| LY2 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.137 | uM | 9536.006 | 1.1079 | 1.1700 | 1.2564 | |
| LY2 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.685 | uM | 9536.006 | 0.9822 | 0.9716 | 1.2564 | |
| LY2 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 10264.026 | 0.9732 | 0.9642 | 1.5047 | |
| LY2 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 10264.026 | 1.0352 | 1.0466 | 1.5047 |